Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

While Eli Lilly leads the GLP-1 weight loss drug market with strong sales growth, Novo Nordisk's new pill version of Wegovy is attracting new customers and offers better value. Eli Lilly's stock is richly valued at 37x P/E with a 0.65% dividend yield, whereas Novo Nordisk trades at 10x P/E with a 4% yield, making it more attractive for dividend and value investors despite near-term pricing pressures.